Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Pfizer to acquire Baxter’s vaccines portfolio

Pfizer to acquire Baxter’s vaccines portfolio

31st July 2014

Pfizer has agreed a deal to acquire Baxter International's portfolio of marketed vaccines, as well as a portion of the company's facility in Orth, Austria, where these products are manufactured.

The $635 million (376.31 million pounds) deal will give Pfizer access to a range of new vaccines, including the meningitis prevention agent NeisVac-C and FSME-IMMUN/TicoVac, a vaccine that helps protect against tick-borne encephalitis.

NeisVac-C has been shown to be highly effective in preventing against group C meningococcal meningitis, one of the most prevalent meningococcal serogroups in many parts of the world.

Meanwhile, FSME-IMMUN/TicoVac is approved in 30 countries and has been marketed for more than 30 years, with approximately 120 million doses produced since 1976. 

Susan Silbermann, Pfizer Vaccines president, said: "We are working hard to bring innovative vaccines to market that prevent and treat serious diseases. Through this acquisition, we will add two high-quality and life-saving vaccines that bring scale and depth to our portfolio."

This comes after the firm announced its financial results for the second quarter of 2014 earlier this week, revealing reported revenues of $12.8 billion for the period.ADNFCR-8000103-ID-801738882-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.